Tempest Therapeutics, Inc.
TPSTTempest Therapeutics, Inc. in brief
Tempest Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Brisbane, California, USA. Its market value was $10 M on 27 October 2026, which makes it the 25,833rd largest listed company in the world and the 4,295th largest in the USA on this site. Matthew Angel is its chief executive. Its shares trade under the symbol TPST (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Tempest Therapeutics, Inc.
We are a clinical-stage biotechnology company advancing a diversified portfolio of cell therapy and small molecule product candidates. In February 2026, we expanded our pipeline through a strategic transaction under which we acquired rights to a portfolio of dual-targeting chimeric antigen receptor T-cells product candidates with the potential to treat certain blood cancers, solid tumors and immunology indications, including TPST-2003, an autologous CD19/B-cell maturation antigen CAR-T therapy currently in clinical development for relapsed or refractory multiple myeloma.
Our portfolio also includes two clinical-stage small molecule product candidates with the potential to treat certain cancer indications. One of our small-molecule product candidates, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma. Amezalpat remains Phase 3-ready in HCC and we plan to pursue business development discussions to advance pivotal development. Our second small-molecule product candidate is TPST-1495, which we plan to initiate a Phase 2 study for in familial adenomatous polyposis, with first patient enrollment expected in 2026. The study is expected to be funded by the National Cancer Institute and conducted through the Cancer Prevention Clinical Trials Network, enabling advancement with limited internal capital deployment.
From the company's annual report filed with the US SEC: read the report
Tempest Therapeutics, Inc. timeline
- 2012
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2018
- ✎Renamed Millendo Therapeutics, Inc.Formerly OvaScience, Inc..
- 2021
- ✎Renamed Tempest Therapeutics, Inc.Formerly Millendo Therapeutics, Inc..
Events of Tempest Therapeutics, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #5,144 (Jan 2022) · #5,472 (Dec 2022) · #5,363 (Jul 2023) · #3,779 (Jan 2024) · #2,370 (Mar 2026) · #3,976 (Aug 2026) · #4,174 (Oct 2026) · #4,297 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 1.5×
- Free cash flow yield
- -262.9%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -393.7%
- Liabilities / assets
- 60.6%
- Net debt
- $-24M
- Revenue growth
- -53.8%
- R&D / revenue
- 6113.3%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-27M | $-26M | — |
| Dec 2024 | — | — | $-42M | $-42M | — |
| Dec 2023 | — | — | $-29M | $-29M | — |
| Dec 2022 | — | — | $-35M | $-36M | — |
| Dec 2021 | — | — | $-27M | $-28M | — |
| Dec 2020 | — | — | $-19M | $-19M | — |
| Dec 2019 | — | — | $-45M | $-45M | — |
| Dec 2018 | — | — | $-27M | $-27M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-27M | $0M | $-27M | $-6.33 | — |
| Dec 2024 | $-33M | $0M | $-33M | $-19.50 | — |
| Dec 2023 | $-27M | $0M | $-28M | $-1.91 | — |
| Dec 2022 | $-31M | $1M | $-32M | $-3.09 | — |
| Dec 2021 | $-26M | $0M | $-26M | $-7.47 | — |
| Dec 2020 | $-19M | $0M | $-19M | $-41.03 | $0.00 |
| Dec 2019 | $-41M | $0M | $-42M | $-3.25 | $0.00 |
| Dec 2018 | $-24M | $0M | $-24M | $-17.58 | $0.00 |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-4M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Nov 12, 20268-KCurrent reportRegulation FD disclosure · Other events
- Nov 10, 20268-KCurrent reportShareholder vote
- Nov 6, 20268-KCurrent reportListing notice
- Oct 30, 20268-KCurrent reportDirectors or officers changed
- Oct 26, 2026DEF 14AProxy statement
- Oct 20, 20268-KCurrent reportShareholder vote · Other events
- Oct 19, 20268-KCurrent reportDirectors or officers changed · Regulation FD disclosure
- Sep 28, 20268-KCurrent reportMaterial agreement · Directors or officers changed · Regulation FD disclosure
- Sep 17, 20268-KCurrent reportMaterial agreement · Regulation FD disclosure
- Sep 16, 20268-KCurrent reportShareholder vote · Other events
- Sep 15, 20268-KCurrent reportMaterial agreement · Unregistered share sale
- Aug 24, 20268-KCurrent reportDirectors or officers changed
Official filings of Tempest Therapeutics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-27 M
- Net income
- $-26 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $17 M
- Total liabilities
- $10 M
- Total equity
- $7 M
As of December-2025
Top 23 institutional investors in Tempest Therapeutics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 233,888 | 0 (0.00%) | 1.17% | $0 M | Nov 13, 2026 |
| 2 | Geode Capital Management, LLC | 74,076 | -12,549 (-14.49%) | 0.37% | $0 M | Nov 6, 2026 |
| 3 | Vanguard Fiduciary Trust Co | 68,908 | 0 (0.00%) | 0.34% | $0 M | Nov 13, 2026 |
| 4 | BlackRock, Inc. | 39,068 | 0 (0.00%) | 0.20% | $0 M | Nov 13, 2026 |
| 5 | UBS Group AG | 25,170 | +19,534 (+346.59%) | 0.13% | $0 M | Nov 10, 2026 |
| 6 | HRT Financial LP | 21,315 | New | 0.11% | $0 M | Nov 13, 2026 |
| 7 | Northern Trust Corp | 20,136 | 0 (0.00%) | 0.10% | $0 M | Nov 16, 2026 |
| 8 | Citigroup Inc | 15,426 | New | 0.08% | $0 M | Nov 4, 2026 |
| 9 | StoneX Group Inc. | 13,668 | New | 0.07% | $0 M | Nov 3, 2026 |
| 10 | Vanguard Personalized Indexing Management, LLC | 11,672 | New | 0.06% | $0 M | Nov 16, 2026 |
| 11 | TRB Wealth Management, LLC | 10,846 | New | 0.05% | $0 M | Nov 16, 2026 |
| 12 | Nuveen, LLC | 5,958 | New | 0.03% | $0 M | Nov 10, 2026 |
| 13 | Tower Research Capital LLC (TRC) | 4,846 | +924 (+23.56%) | 0.02% | $0 M | Nov 16, 2026 |
| 14 | Morgan Stanley | 2,022 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 15 | Osaic Holdings, Inc. | 1,439 | -74 (-4.89%) | 0.01% | $0 M | Nov 12, 2026 |
| 16 | Federation des caisses Desjardins du Quebec | 292 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 17 | Northwestern Mutual Wealth Management Co | 134 | New | 0.00% | $0 M | Nov 13, 2026 |
| 18 | SBI Securities Co., Ltd. | 56 | 0 (0.00%) | 0.00% | $0 M | Oct 22, 2026 |
| 19 | Royal Bank Of Canada | 28 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 20 | Parallel Advisors, LLC | 18 | 0 (0.00%) | 0.00% | $0 M | Nov 3, 2026 |
| 21 | FMR LLC | 15 | New | 0.00% | $0 M | Nov 10, 2026 |
| 22 | BNP Paribas Financial Markets | 3 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 23 | Caitong International Asset Management Co., Ltd | 1 | -2 (-66.67%) | 0.00% | $0 M | Oct 29, 2026 |
Mutual funds holding Tempest Therapeutics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 128,944 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 104,944 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 50,985 | $0 M | — | <0.01% | +110% | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 15,677 | $0 M | — | <0.01% | +255% | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 7,495 | $0 M | — | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 24,406 | $0 M | — | <0.01% | new | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 7,495 | $0 M | — | <0.01% | new | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 4,421 | $0 M | — | <0.01% | new | May 31, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 35,200 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 104,944 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 10 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Tempest Therapeutics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Matthew AngelCEO and President, Director, 10% owner | Buyindirect | +231,482 | $2.160 | $500 K | 231,482 | Form 4 |
| filed | Matthew AngelCEO and President, Director, 10% owner | Buyindirect | +231,482 | $2.160 | $500 K | 231,482 | Form 4 |
| filed | Versant Venture Capital VI, L.P.10% owner | Sell | -387,999 | $1.100 | $427 K | 209,941 | Form 4 |
| filed | Versant Venture Capital VI, L.P.10% owner | Sell | -400,000 | $1.350 | $540 K | 597,940 | Form 4 |
| filed | Stephen R. BradyPresident and CEO, Director | Buy | +35,000 | $2.110 | $74 K | 46,376 | Form 4 |
| filed | Samuel WhitingChief Medical Officer | Buy | +4,672 | $2.130 | $10 K | 9,573 | Form 4 |
| filed | Justin TrojanowskiCorporate Controller | Buy | +7,500 | $2.160 | $16 K | 22,168 | Form 4 |
| filed | Thomas WoiwodeDirector, 10% owner | Buyindirect | +2.12 M | $2.360 | $5.0 M | 2.12 M | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Tempest Therapeutics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 2.023-for-1 split
Trading halts
- 2025-11-19 15:05 UTC, code LUDP, resumed 15:10 UTC
- 2025-11-19 14:53 UTC, code LUDP, resumed 14:58 UTC
- 2025-11-19 14:41 UTC, code LUDP, resumed 14:51 UTC
- 2025-04-08 23:50 UTC, code T3, resumed 13:00 UTC
Fails to deliver
- : 2,222 shares at $0.51
- : 701 shares at $0.62
- : 8,345 shares at $0.74
- : 14 shares at $0.79
- : 142 shares at $0.81
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Tempest Therapeutics, Inc. scorecard#
Passes 2 of the 11 checks that could be worked out: strongest in valuation (1 of 3), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 27, 2026.
Valuation1 of 3
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median1.5×Price to book 1.5× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- –Free cash flow yield above 5%No free cash flow yield on file.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-6.33 vs -19.50Diluted EPS -6.33 in fiscal 2025 against -19.50 the year before (report's currency).
- ✗Net income higher than five years earlier-$26 M-$26 M in fiscal 2025 against -$19 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$26 MNet income -$26 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-203.6%-203.6% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities2.5×Current ratio 2.50 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year93.4%Diluted shares up 93.4% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Tempest Therapeutics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | — | — | — | — | — | — | — | — | 0.3−54.8%100% | 0.7—100% | |
| Cost of revenue | — | — | — | — | — | — | — | — | 0.8−85.4%268% | 5.4—827% | |
| Research and development | 13−55.7%— | 28+62.7%— | 17−22.3%— | 23+31.2%— | 17+19.3%— | 14r20−48.3%— | 28+93.0%— | 14−21.3%— | 18−15.3%6216% | 22—3314% | |
| Selling, general and administrative | — | — | — | — | — | — | — | — | 28−43.6%9405% | 49—7538% | |
| General and administrative | 14+3.1%— | 14+16.2%— | 12−3.7%— | 12+23.4%— | 9.8+100%— | 4.9r16−72.0%— | 18+102%— | 8.7+45.9%— | 6.0—2019% | — | |
| Operating expenses | — | — | — | — | — | — | — | — | 51−37.7%17255% | 82—12506% | |
| Operating income | −27—— | −42—— | −29—— | −35—— | −27—— | −19r−36—— | −45—— | −27—— | −84r−51—−28585% | −81—−12406% | |
| Interest expense and finance costs | 0.2−84.3%— | 1.3−9.2%— | 1.4−10.4%— | 1.6+26.2%— | 1.3—— | 0—— | — | 0.1−53.5%— | 0.3—97.6% | — | |
| Share of profit of associates | — | — | — | — | — | — | — | — | −1.0—−345% | −1.5—−236% | |
| Other non-operating income (expense) | 0.3+71.0%— | 0.2—— | −0.3—— | −1.1—— | −1.3−1562%— | 0.1—— | — | — | −0.0—−12.2% | −0.2—−25.1% | |
| Income before tax | — | — | — | — | — | — | — | — | −51—−17257% | −82—−12566% | |
| Income tax | 0—— | 0—— | 0—— | 0—— | 0—— | 0—— | — | — | 0.1−66.7%22.7% | 0.2—30.8% | |
| Net income including minority interests | −26—— | −42—— | −29—— | −36—— | −28—— | −19r−36—— | −45—— | −27—— | −85—−28673% | — | |
| Minority interests' share of net income | — | — | — | — | — | — | 0−100%— | 0.0—— | −0.0—−2.7% | — | |
| Net income attributable to shareholders | −26—— | −42—— | −29—— | −36—— | −28—— | −19r−36—— | −45—— | −27—— | −85r−51—−28671% | −82—−12597% | |
| Earnings per share, basic | -6.33—— | -19.50r-1.50—— | -1.91—— | -3.09—— | -7.47—— | -41.03r-1.93—— | -3.25—— | -17.58—— | -321.81r-1.43—— | -2.56—— | |
| Earnings per share, diluted | -6.33—— | -19.50r-1.50—— | -1.91—— | -3.09—— | -7.47—— | -41.03r-1.93—— | -3.25—— | -17.58—— | -321.81r-1.43—— | -2.56—— | |
| Shares, weighted average (basic) | 4.1+93.3%— | 2.1r28−86.1%— | 15+33.5%— | 12+205%— | 3.8+710%— | 0.5—— | — | — | — | — | |
| Shares, weighted average (diluted) | 4.1+93.3%— | 2.1r28−86.1%— | 15+33.5%— | 12+205%— | 3.8+710%— | 0.5r19−96.6%— | 14+786%— | 1.5+489%— | 0.3r36−99.2%— | 32—— | |
| Dividends per share | — | — | — | — | — | 0.00—— | 0.00—— | 0.00—— | — | — | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 7.7−74.5%45.5% | 30−22.8%73.0% | 39+25.6%76.0% | 31−39.7%67.8% | 52+175%70.8% | 19r38−69.9%82.3% | 62−14.7%83.3% | 73+317%87.2% | 18r16−60.0%88.7% | 44—35.8% | |
| Short-term investments | — | — | — | — | — | — | — | 0−100%0.0% | 52−26.9%260% | 70—57.5% | |
| Other current assets | 0.4−33.6%2.1% | 0.5+457%1.3% | 0.1−63.5%0.2% | 0.3−52.4%0.6% | 0.6+837%0.8% | 0.1r1.9−99.1%0.3% | 6.3+88.1%8.5% | 3.4+211%4.0% | 1.1r1.6−47.3%5.5% | 2.1—1.7% | |
| Current assets | 8.3−73.7%48.8% | 31−22.0%75.9% | 40+22.5%78.2% | 33−52.2%71.5% | 69+248%94.2% | 20r41−72.1%86.7% | 71−14.7%94.9% | 83+323%99.2% | 20r69−83.0%99.6% | 116—95.0% | |
| Property, plant and equipment | 0.6−31.7%3.6% | 0.9+5.5%2.1% | 0.8−20.8%1.6% | 1.1−4.8%2.3% | 1.1+0.3%1.5% | 1.1—4.9% | — | — | 3.1−44.1%15.7% | 5.6—4.5% | |
| Right-of-use (leased) assets | 7.5−12.8%44.5% | 8.6−13.2%20.8% | 10.0−14.6%19.3% | 12+282%25.3% | 3.1+62.5%4.2% | 1.9r2.2−43.7%8.2% | 3.3—4.4% | — | — | — | |
| Investments in associates | — | — | — | — | — | — | — | — | 0.1+125%0.7% | 0.1—0.1% | |
| Total assets | 17−59.2%100% | 41−19.6%100% | 52+12.0%100% | 46−37.1%100% | 73+220%100% | 23r43−69.5%100% | 75−10.8%100% | 84+324%100% | 20r73−83.8%100% | 123—100% | |
| Accounts payable | 1.0−57.6%6.1% | 2.5+190%5.9% | 0.8−23.7%1.6% | 1.1+11.8%2.4% | 1.0−7.5%1.4% | 1.1r1.5−28.4%4.7% | 1.5−25.2%2.0% | 2.0+53.9%2.4% | 1.3r2.2−40.5%6.6% | 2.2—1.8% | |
| Debt due within a year | 0−100%0.0% | 6.4+48.3%15.3% | 4.3—8.3% | — | — | 0.2+14.9%1.0% | 0.2+10.1%0.3% | 0.2+8.6%0.2% | 0.2—0.9% | — | |
| Current liabilities | 3.3−76.7%19.6% | 14+51.1%34.3% | 9.4+29.3%18.2% | 7.3−63.7%15.8% | 20+522%27.3% | 3.2r8.0−74.3%14.1% | 13+27.5%16.7% | 9.8+140%11.7% | 4.1r7.8−69.0%20.6% | 13—10.8% | |
| Long-term debt | — | 0−100%0.0% | 6.3−39.6%12.1% | 10−31.2%22.5% | 15—20.6% | 0r0.1−100%0.0% | 0.2−56.1%0.2% | 0.4−36.1%0.5% | 0.6—3.0% | — | |
| Lease liabilities (non-current) | 6.9−14.7%41.0% | 8.1−11.1%19.6% | 9.2−11.3%17.8% | 10+410%22.4% | 2.0+17.3%2.8% | 1.7r1.6−27.9%7.6% | 2.4—3.2% | — | — | — | |
| Total liabilities | 10−54.1%60.6% | 22−10.0%53.9% | 25−11.2%48.1% | 28−24.6%60.7% | 37+650%50.7% | 4.9r9.7−67.2%21.6% | 15+37.9%20.1% | 11+127%13.0% | 4.8r8.6−66.3%24.4% | 14—11.7% | |
| Retained earnings | −233—−1378% | −207—−499% | −165—−320% | −136—−295% | −100—−137% | −72r−245—−314% | −209—−278% | −164—−195% | −137r−301—−691% | −250—−204% | |
| Shareholders' equity | 6.7−65.1%39.4% | 19−28.5%46.1% | 27+47.8%51.9% | 18−49.9%39.3% | 36—49.3% | −69r33—−301% | −50r59−171%−67.2% | 71—84.4% | −131r64−221%−660% | 108—88.3% | |
| Minority interests | — | — | — | — | — | 0.7−49.5%2.9% | 1.3−39.0%1.8% | 2.20.0%2.6% | 2.2—11.0% | — | |
| Total equity | 6.7−65.1%39.4% | 19−28.5%46.1% | 27+47.8%51.9% | 18−49.9%39.3% | 36—49.3% | −69r34−215%−301% | 60−18.1%79.9% | 73—87.0% | −129—−649% | −51—−41.8% | |
| Total liabilities and equity | 17−59.2%100% | 41−19.6%100% | 52+12.0%100% | 46−37.1%100% | 73+220%100% | 23r43−69.5%100% | 75−10.8%100% | 84+324%100% | 20r73−83.8%100% | 123—100% | |
| Shares outstanding | 4.9+45.7%— | 3.4r44−84.7%— | 22+110%— | 11+52.2%— | 6.9+1211%— | 0.5r19−97.1%— | 18+36.7%— | 13+5322%— | 0.2r36−99.3%— | 36—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | — | — | — | — | — | — | — | — | 1.7−26.3%559% | 2.2—343% | |
| Share-based compensation | 3.1−41.2%— | 5.3+108%— | 2.5+63.1%— | 1.6+41.3%— | 1.1+144%— | 0.5r4.2−89.5%— | 4.3+203%— | 1.4−79.3%— | 6.9−25.2%2337% | 9.2—1411% | |
| Cash from operating activities | −27—— | −33—— | −27—— | −31—— | −26—— | −19r−30—— | −41—— | −24—— | −20r−46—−6895% | −62—−9454% | |
| Capital expenditure | 0—— | −0.4—— | −0.2—— | −0.6—— | −0.1—— | −0.1r−0.0—— | −0.4—— | −0.0—— | −0.0r−0.2—−1.4% | −2.6—−396% | |
| Acquisitions, net of cash acquired | — | — | — | — | — | — | 0—— | −0.5—— | −0.5—−157% | — | |
| Cash from investing activities | 0—— | −0.4—— | −0.2—— | −0.6—— | −0.1—— | −0.0r−0.0−100%— | 4.0+106%— | 1.9+322%— | 0.5r17−94.5%155% | 8.3—1270% | |
| Debt issued | — | — | — | — | 15—— | 0—— | — | — | 6.0—2034% | — | |
| Debt repaid | −6.4—— | −4.4—— | — | −4.7—— | — | −0.1—— | −0.2—— | −0.2—— | −10—−3404% | — | |
| Shares issued | 6.0−78.9%— | 29−19.7%— | 36+302%— | 8.9−73.5%— | 33—— | 0r5.5−100%— | 27—— | 0—— | 0−100%0.0% | 54—8258% | |
| Cash from financing activities | 4.3−82.6%— | 25−31.2%— | 36+212%— | 11−80.7%— | 59+70.7%— | 35r5.4+28.4%— | 27−65.3%— | 78—— | −4.5r0−108%−1513% | 54—8292% | |
| Exchange-rate effect on cash | — | — | — | — | — | 0.2+570%— | 0.0−72.0%— | 0.1+521%— | 0.0—6.4% | — | |
| Change in cash | — | — | — | — | — | −25—— | −10−118%— | 56—— | −24—−8246% | — | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Research and development | 2.7−88.3%— | 0.2−63.7%— | 1.8−53.0%— | 0.1−98.5%— | 0.5*−95.0%— | 0.6−92.5%— | 3.9−33.7%— | 7.6+75.7%— | 11*+157%— | 7.6—— | 5.8—— | 4.3—— | 4.2*—— | |
| General and administrative | 15+10.3%— | 2.6−13.6%— | 3.4−16.2%— | 5.4+63.9%— | 3.5*+11.4%— | 3.0+1.1%— | 4.1+9.3%— | 3.3−8.9%— | 3.2*−4.7%— | 3.0—— | 3.7—— | 3.6—— | 3.3*—— | |
| Operating income | −40—— | −2.8—— | −5.3—— | −28—— | −4.1*—— | −3.6—— | −8.0—— | −11—— | −14*—— | −11—— | −9.6—— | −8.0—— | −7.5*—— | |
| Interest expense and finance costs | — | — | 0−100%— | 0−100%— | 0*−100%— | 0−100%— | 0.0−87.6%— | 0.2−56.3%— | 0.2*−34.5%— | 0.3—— | 0.4—— | 0.4—— | 0.4*—— | |
| Other non-operating income (expense) | −0.7−299%— | −0.8−1037%— | 0.0−93.8%— | 0.0−69.7%— | 0.1*−46.7%— | 0.1—— | 0.1+700%— | 0.1+8.6%— | 0.1*+304%— | −0.0—— | 0.0—— | 0.1—— | 0.0*—— | |
| Income tax | — | — | 0—— | 0—— | 0*—— | 0—— | 0—— | 0—— | 0*—— | 0—— | 0—— | 0—— | 0*—— | |
| Net income including minority interests | −41—— | −3.6—— | −5.2—— | −28—— | −4.0*—— | −3.5—— | −7.9—— | −11—— | −14*—— | −11—— | −9.6—— | −7.9—— | −7.5*—— | |
| Net income attributable to shareholders | −41—— | −3.6—— | −5.2—— | −28—— | −4.0*—— | −3.5—— | −7.9—— | −11—— | −14*—— | −11—— | −9.6—— | −7.9—— | −7.5*—— | |
| Earnings per share, basic | — | -0.21—— | -0.34—— | -2.53—— | — | -0.79—— | -2.07—— | -3.16—— | — | -5.32r-0.41—— | -5.52r-0.42—— | -4.62r-0.36—— | — | |
| Earnings per share, diluted | — | -0.21—— | -0.34—— | -2.53—— | — | -0.79—— | -2.07—— | -3.16—— | — | -5.32r-0.41—— | -5.52r-0.42—— | -4.62r-0.36—— | — | |
| Shares, weighted average (basic) | 17+281%— | 17+281%— | 15+300%— | 11+218%— | — | 4.4+124%— | 3.8+119%— | 3.4+101%— | — | 2.0r26—— | 1.7r23—— | 1.7r22—— | — | |
| Shares, weighted average (diluted) | 17+281%— | 17+281%— | 15+300%— | 11+218%— | — | 4.4+124%— | 3.8+119%— | 3.4+101%— | — | 2.0r26—— | 1.7r23—— | 1.7r22—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 0.9—10.2% | 0.9−88.1%10.2% | 0.8−94.5%8.1% | 1.8−91.6%16.8% | 7.7−74.5%45.5% | 7.5−66.0%43.9% | 14−54.1%58.3% | 22−33.5%66.9% | 30−22.8%73.0% | 22—65.4% | 31—73.8% | 32—72.8% | 39—76.0% | |
| Other current assets | 0.4—4.8% | 0.4+18.5%4.8% | 0.4−13.5%4.3% | 0.0−99.2%0.0% | 0.4−33.6%2.1% | 0.4−8.6%2.1% | 0.5+1277%2.0% | 0.4−24.1%1.1% | 0.5+457%1.3% | 0.4—1.1% | 0.0—0.1% | 0.5—1.1% | 0.1—0.2% | |
| Current assets | 1.6—18.4% | 1.6−80.1%18.4% | 1.7−88.8%17.6% | 2.4−89.1%22.8% | 8.3−73.7%48.8% | 8.1−65.6%47.3% | 15−52.1%61.7% | 22−33.0%69.7% | 31−22.0%75.9% | 24—69.6% | 32—74.8% | 33—75.5% | 40—78.2% | |
| Property, plant and equipment | 0.4—4.9% | 0.4−37.0%4.9% | 0.5−35.0%5.0% | 0.5−33.3%5.1% | 0.6−31.7%3.6% | 0.7−26.9%4.0% | 0.7−26.2%3.1% | 0.8−11.2%2.5% | 0.9+5.5%2.1% | 0.9—2.8% | 1.0—2.4% | 0.9—2.1% | 0.8—1.6% | |
| Right-of-use (leased) assets | 6.6—75.8% | 6.6−15.1%75.8% | 6.9−14.3%72.1% | 7.2−13.5%67.4% | 7.5−12.8%44.5% | 7.8−12.1%45.7% | 8.1−11.5%33.1% | 8.4−12.0%26.0% | 8.6−13.2%20.8% | 8.9—26.3% | 9.2—21.7% | 9.5—21.4% | 10.0—19.3% | |
| Total assets | 8.8—100% | 8.8−48.9%100% | 9.6−60.7%100% | 11−66.6%100% | 17−59.2%100% | 17−49.4%100% | 24−41.9%100% | 32−27.5%100% | 41−19.6%100% | 34—100% | 42—100% | 44—100% | 52—100% | |
| Accounts payable | 2.0—23.2% | 2.0+120%23.2% | 2.0−57.7%20.7% | 0.6−73.3%5.4% | 1.0−57.6%6.1% | 0.9−45.7%5.4% | 4.7+248%19.3% | 2.2+108%6.8% | 2.5+190%5.9% | 1.7—5.0% | 1.4—3.2% | 1.1—2.4% | 0.8—1.6% | |
| Debt due within a year | — | — | — | — | 0−100%0.0% | 0−100%0.0% | 0−100%0.0% | 4.2−35.1%13.0% | 6.4+48.3%15.3% | 8.5—25.1% | 8.6—20.5% | 6.5—14.6% | 4.3—8.3% | |
| Current liabilities | 4.7—53.3% | 4.7+32.5%53.3% | 4.5−37.7%46.2% | 3.3−74.9%30.8% | 3.3−76.7%19.6% | 3.5−74.8%20.6% | 7.1−51.0%29.2% | 13+23.3%41.0% | 14+51.1%34.3% | 14—41.3% | 15—34.5% | 11—24.1% | 9.4—18.2% | |
| Long-term debt | — | — | — | — | — | — | — | — | 0−100%0.0% | 0—0.0% | 2.0—4.8% | 4.1—9.3% | 6.3—12.1% | |
| Lease liabilities (non-current) | 5.9—67.6% | 5.9−18.4%67.6% | 6.3−17.0%65.1% | 6.6−15.8%61.5% | 6.9−14.7%41.0% | 7.3−13.7%42.4% | 7.6−12.7%30.9% | 7.9−11.9%24.4% | 8.1−11.1%19.6% | 8.4—24.8% | 8.7—20.5% | 8.9—20.1% | 9.2—17.8% | |
| Total liabilities | 11—121% | 11−1.8%121% | 11−27.1%111% | 9.9−52.8%92.4% | 10−54.1%60.6% | 11−51.8%63.0% | 15−41.7%60.0% | 21−11.4%65.4% | 22−10.0%53.9% | 22—66.1% | 25—59.8% | 24—53.5% | 25—48.1% | |
| Retained earnings | −279—−3184% | −279—−3184% | −275—−2858% | −270—−2513% | −233—−1378% | −229—−1339% | −226—−922% | −218—−678% | −207—−499% | −193—−571% | −183—−433% | −173—−390% | −165—−320% | |
| Shareholders' equity | −1.8—−20.9% | −1.8−129%−20.9% | −1.1−111%−11.3% | 0.8−92.6%7.6% | 6.7−65.1%39.4% | 6.3−44.6%37.0% | 9.8−42.2%40.0% | 11−46.0%34.6% | 19−28.5%46.1% | 11—33.9% | 17—40.2% | 21—46.5% | 27—51.9% | |
| Total equity | −1.8—−20.9% | −1.8−129%−20.9% | −1.1−111%−11.3% | 0.8−92.6%7.6% | 6.7−65.1%39.4% | 6.3−44.6%37.0% | 9.8−42.2%40.0% | 11−46.0%34.6% | 19−28.5%46.1% | 11—33.9% | 17—40.2% | 21—46.5% | 27—51.9% | |
| Total liabilities and equity | 8.8—100% | 8.8−48.9%100% | 9.6−60.7%100% | 11−66.6%100% | 17−59.2%100% | 17−49.4%100% | 24−41.9%100% | 32−27.5%100% | 41−19.6%100% | 34—100% | 42—100% | 44—100% | 52—100% | |
| Shares outstanding | 17—— | 17+280%— | 16+260%— | 14+308%— | 4.9+45.7%— | 4.4−83.3%— | 4.4−81.9%— | 3.5−84.2%— | 3.4r44−84.7%— | 27—— | 24—— | 22—— | 22—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 0.6−83.7%— | −0.1−189%— | −0.1−111%— | 0.2−83.7%— | 0.6*−56.7%— | 0.1−95.4%— | 1.1−17.3%— | 1.4+5.4%— | 1.3*+21.3%— | 1.3—— | 1.3—— | 1.3—— | 1.1*—— | |
| Cash from operating activities | −16—— | −2.1*—— | −2.8*—— | −7.6—— | −3.6*—— | −6.8*—— | −8.4*—— | −8.0—— | −10*—— | −10*—— | −5.5*—— | −7.2—— | −6.2*—— | |
| Capital expenditure | — | — | 0*—— | 0—— | 0*—— | 0*—— | 0*—— | 0—— | −0.0*—— | −0.0*—— | −0.2*—— | −0.2—— | −0.0*—— | |
| Cash from investing activities | — | — | 0*—— | 0—— | 0*—— | 0*—— | 0*—— | 0—— | −0.0*—— | −0.0*—— | −0.2*—— | −0.2—— | −0.0*—— | |
| Debt repaid | — | — | 0*—— | 0—— | 0*—— | 0*—— | −4.2*—— | −2.2—— | −2.2*—— | −2.2*—— | — | — | — | |
| Shares issued | — | — | — | — | 1.0*−94.9%— | 0*−100%— | 3.6*−21.7%— | 1.4+470%— | 20*−41.3%— | 3.6*—— | 4.6*—— | 0.3—— | 34*—— | |
| Cash from financing activities | 9.4−49.1%— | 2.2*+16592%— | 1.8*+46.1%— | 1.7—— | 3.8*−79.0%— | 0.0*−99.2%— | 1.2*−73.7%— | −0.7−260%— | 18*−47.7%— | 1.5*—— | 4.6*—— | 0.5—— | 34*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Executive pay at Tempest Therapeutics, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Mr. Brady | $2.3 M | $1.5 M | $1.0 M | $19 |
| 2024Mr. Brady | $1.9 M | −$1.7 M | $842 K | $16 |
| 2023Mr. Brady | $7.0 M | $4.4 M | $2.4 M | $83 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Tempest Therapeutics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
Delisting notice 3 · Change in control 1 · Acquisition or sale completed 1 · Directors and officers 9 · Material agreement 8 · Unregistered share sale 5 · Shareholder rights changed 1 · Shareholder vote 7 · Results announced 3
| Filed | What happened | Filing |
|---|---|---|
| Shareholder vote | 8-K | |
| Delisting notice | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Directors and officersMaterial agreement | 8-K | |
| Material agreement | 8-K | |
| Shareholder vote | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Material agreement | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Change in controlAcquisition or sale completedDirectors and officersMaterial agreementUnregistered share sale | 8-K | |
| Directors and officersShareholder rights changedShareholder vote | 8-K | |
| Delisting notice | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026
Acquisitions and funding#
3 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Sep 2026 | $8 M | Private placement after listing | $2 to $10 million | 1 | options | SEC |
| May 2026 | $4 M | Private placement after listing | $2 to $10 million | 1 | equity, options | SEC |
| Mar 2026 | $2 M | Private placement after listing | $2 to $10 million | 3 | equity, options | SEC |
| Apr 2022 | $15 M | Private placement after listing | $10 to $50 million | 2 | equity, options | SEC |
| Mar 2013 | $35 M | No. 3 | $10 to $50 million | 31 | equity | SEC |
| Jun 2012 | $5 M | No. 2 | $2 to $10 million | 253 | equity | SEC |
| Mar 2012 | $37 M | No. 1 | $10 to $50 million | 19 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | · | · | · | 26 | · | · | · | · | · | · | · | · | 26 |
| 2021 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| 2020 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| 2018 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| 2017 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 26 people | Restructuring planSEC 8-K | “As part of the plan, the Company will reduce its workforce by 21 of 26 full-time employees, effective April 30, 2025.” | Filing | |
| 85% of workforce | Restructuring planSEC 8-K | “In connection with the Plan, the Company plans to reduce its workforce by up to 85%, with the majority of the reduction in personnel expected to be completed by April 15, 2021.” | Filing | |
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing | |
| 70% of workforce | Restructuring planSEC 8-K | “In connection with the restructuring plan, the Company plans to reduce its workforce by approximately 70%, with the majority of the reduction in personnel expected to be completed …” | Filing | |
| 50% of workforce | Restructuring planSEC 8-K | “(“OvaScience” or the “Company”) announced that it will restructure its organization to reduce its workforce by approximately 50% in connection with its determination that its strat…” | Filing | |
| 50% of workforce | Restructuring planSEC 8-K | “(“OvaScience” or the “Company”) announced that it (i) continues to be focused on advancing its two potentially transformative fertility treatments, OvaTure SM , in preclinical deve…” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Tempest Therapeutics, Inc. compares in Biotechnology
- Market cap$10 M · higher than 11% of 726
- Revenue growth-53.9% · higher than 16% of 438
- Price / book1.5× · lower than 66% of 534
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Tempest Therapeutics, Inc.🇺🇸 | $10 M | — | — | -53.9% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 27, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Tempest Therapeutics, Inc.? Verify and update this profile — free
Show Tempest Therapeutics, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.